Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

Cytokine

Volumn 77, Issue , 2016, Pages 245-247

  Corrales, Leticia ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

STING pathway; Tumor immunology; Type I IFN

Indexed keywords

ADENOSINE PHOSPHATE; BINDING PROTEIN; CYCLIC DINUCLEOTIDE DERIVATIVE; CYCLIC GMP; DINUCLEOTIDE; DNA; INTERFERON REGULATORY FACTOR 3; MEMBRANE PROTEIN; PROTEIN STING; PROTEIN TBK1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VADIMEZAN; MPYS PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; HUMAN; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BIOLOGICAL MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MEMBRANE PROTEINS; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84949096097     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.08.258     Document Type: Article

References (10)

1. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
2. Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:268-276.
3. + T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
4. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208:1989-2003.
5. + dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
6. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
7. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
8. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
9. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
10. Corrales L., Glickman L.H., McWhirter S.M., Kanne D.B., Sivick K.E., Katibah G.E., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015, 11:1018-1030.